 The aim of this study is to evaluate the role of cognitive disorders and quality of life in patients with CIS, considered as high risk to develop an MS, treated with interferon Beta. This prospective observational study will include 120 patients, all treated and evaluated annually with neurological extensive examination, ophthalmologic screening OCT, OF, VEP, VF, auto questionnaire about fatigue musicol, ELIF, quality of life SEP-59, and conventional MRI. 